Identification of MBT3T as a new effective therapeutic option in imatinib-resistant gastrointestinal stromal tumors (GISTs) - PubMed
4 hours ago
- #TKI resistance
- #GIST
- #Tubulin
- MBT3T identified as a new therapeutic option for imatinib-resistant GISTs.
- Study involves human blood samples and zebrafish embryos, adhering to ethical guidelines.
- Authors declare no competing interests.
- References discuss GIST treatment advancements, pharmacogenetics, and classification of wild-type GISTs.